Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (49,308)	$ (48,244)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	520	349
Amortization of intangible assets	499	500
Stock-based compensation	4,443	10,990
Reserve for excessive and obsolete inventory	7,371
Net premium amortization and discount on available-for-sale securities		13
Changes in operating assets and liabilities:
Accounts receivable	56	(72)
Inventory	(2,297)	(4,281)
Prepaid expenses and other current assets	940	(2,087)
Other receivables	(53)	32
Right-of-use assets	535	484
Accounts payable	(895)	975
Accrued expenses	(407)	(355)
Deferred revenue	22	7
Lease liabilities	(573)	(365)
Accrued interest on related party note payable	98	629
Accrued interest on note payable	1	22
Net cash used in operating activities	(39,048)	(41,403)
Cash flows from investing activities:
Purchases of property and equipment	(360)	(303)
Maturities of investments		8,000
Net cash provided by (used in) investing activities	(360)	7,697
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock purchase plan	485	810
Proceeds from exercises of warrants	15	4,217
Proceeds from exercises of stock options		678
Proceeds from issuance of common stock	14,893	56,697
Proceeds from issuance of related party note	65,000	1,939
Tax payments related to shares withheld for vested restricted stock units		(232)
Payments made on insurance loan agreement	(437)	(875)
Net cash provided by financing activities	79,956	63,234
Net increase in cash and cash equivalents	40,548	29,528
Cash and cash equivalents at beginning of period	28,614	12,463
Cash and cash equivalents at end of period	69,162	41,991
Supplemental disclosure of noncash investing and financing activities:
Equipment purchases included in accounts payable and accrued expenses	(16)	14
Change in unrealized gains on available-for-sale securities		1
Accrued interest settled via issuance of common stock from private placement equity offering		$ 629
Issuance costs for rights offering in accounts payable	$ (29)